Medical service utilisation, economic burden and health status of patients with rare diseases in China

doi:10.5246/jcps.2018.05.037

Abstract

Abstract:

Many patients with rare diseases not only suffer from more severe conditions but often receive less disease management,which is one significant public health concern globally. Few practice-based surveys focus on the care of patients with rare diseases. In the present study, we aimed to investigate medical service utilization, economic burden and health status of patients with rare diseases in China. A cross-sectional questionnaire survey focusing on patients with rare diseases was conducted. Descriptive analysis was conducted to examine the sociodemographic characteristics, medical service utilization, economic burden and health status. Logistic regression analysis was applied to explore influencing factors of self-rated health. A total of 982 patients with 81 types of diseases were included in this survey. We found that 58.2% of patients experienced misdiagnosis, and 35.2% of the patients were misdiagnosed for at least five times. Moreover, 65.8% of patients traveled to hospitals to seek medical services, and 92.1% of patients paid expenses for their treatment. However, only 1.3% of patients could afford their medical expenditure without debts, and 86.8% of patients regarded their health status as bad or moderate. Significant factors correlated with health status were economic status, gender, age, employment and household size. From this study, the accessibility of medical service utilization, the affordability of medical economic burden, and the condition of health status for patients with rare disease in China were considerably poor. Basic medical insurance did not play its role in improving the utilization of medical services and the affordability of medical costs. Social support should be encouraged to improve patients’ health status.

Key words: Medical service utilization, Economic burden, Health status, Rare diseases

CLC Number:

R951

Supporting:

Mengyuan Fu, Xiaodong Guan, Guoxu Wei, Xiaoxiong Xin, Luwen Shi. Medical service utilisation, economic burden and health status of patients with rare diseases in China[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(5): 361-369.

References

[1] Cui, Y.; Han, J. A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs. Orphanet. J. Rare Dis. 2015, 10, 28.

[2] The 107th Congress United States Congress. Rare Disease Act of 2002. https://www.govtrack.us/congress/bills/107/hr4013 (accessed March 18, 2017)

[3] European Parliament. Regulation (EC) No. 1901/2006 on medicinal products for paediatric use and amending. http://www.wipo.int/wipolex/en/details.jsp?id=5940b (accessed March 18, 2017)

[4] Hayashi, S.; Umeda, T. 35 years of Japanese policy on rare diseases. Lancet. 2008, 372, 889-890.

[5] Song, P.; Gao, J.; Inagaki, Y.; Kokudo, N.; Tang, W. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable Rare Dis. Res. 2012, 1, 3-9.

[6] Achelrod, D.; Blankart, C.R.; Linder, R.; von Kodolitsch, Y.; Stargardt, T. The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study. Orphanet. J. Rare Dis. 2014, 9, 90.

[7] Kanters, T.A.; de Sonneville-Koedoot, C.; Redekop, W.K.; Hakkaart, L. Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Orphanet. J. Rare Dis. 2013, 8, 124.

[8] Kevany, S.; Murima, O.; Singh, B.; Hlubinka, D.; Kullch, M.; Morin, S.F.; Sweat, M. Socio-economic status and health care utilisation in rural Zimbabwe: findings from Project Accept (HPTN 043). J. Public Health Africa. 2012, 3, 46-51.

[9] Aygoren-Pursun, E.; Bygum, A.; Beusterien, K.; Hautamaki, E.; Sisic, Z.; Wait, S.; Boysen, H.B.; Caballero, T. Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J. Rare Dis. 2014, 9, 99.

[10] Henrard, S.; Devleesschauwer, B.; Beutels, P.; Callens, M.; De Smet, F.; Hermans, C.; Speybroeck, N. The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. Orphanet. J. Rare Dis. 2014, 9, 39.

[11] Hime, N.J.; Fitzgerald, D.; Robinson, P.; Selvadurai, H.; Van, A.P.; Jaffé, A.; Zurynski, Y. Childhood interstitial lung disease due to surfactant protein C deficiency: frequent use and costs of hospital services for a single case in Australia. Orphanet. J. Rare Dis. 2014, 9, 36.

[12] Weinreb, N.J.; Finegold, D.N.; Feingold, E.; Zeng, Z.; Rosenbloom, B.E.; Shankar, S.P.; Amato, D. Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3). Orphanet. J. Rare Dis. 2015, 10, 64.

[13] Rollet, P.; Lemoine, A.; Dunoyer, M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet. J. Rare Dis. 2013, 8, 109.

[14] Polistena, B.; Spandonaro, F.; Zocchetti, C.; Daina, E. Epidemiology and Healthcare Services Utilisation for Rare Diseases in Italy. Value Health. 2015, 18, A681.

[15] Angelis, A.; Tordrup, D.; Kanavos, P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy. 2015, 119, 964-979.

[16] Giunti, P.; Greenfield, J.; Stevenson, A.J.; Parkinson, M.H.; Hartmann, J.L.; Sandtmann, R.; Piercy, J.; O’Hara, J.; Casas, L.R.; Smith, F.M. Impact of Friedreich’s Ataxia on health-care resource utilisation in the United Kingdom and Germany. Orphanet. J. Rare Dis. 2013, 8, 38.

[17] Johansen, H.; Andresen, I.L.; Naess, E.E.; Hagen, K.B. Health status of adults with Short Stature: A comparison with the normal population and one well-known chronic disease (Rheumatoid Arthritis). Orphanet J. Rare Dis. 2007, 2, 10.

[18] Benyamini, Y.; Boyko, V.; Blumstein, T.; Lerner-Geva, L. Health, cultural and socioeconomic factors related to self-rated health of long-term Jewish residents, immigrants, and Arab women in midlife in Israel. Women Health. 2014, 54, 402-424.

[19] Mudde, C. Racist Extremism in Central and Eastern Europe. East Europ. Politics Societies. 2005, 19, 161-184.

[20] Ohara, Y.; Hirano, H.; Watanabe, Y.; Obuchi, S.; Yoshida, H.; Fujiwara, Y.; Ihara, K.; Kawai, H.; Mataki, S. Factors associated with self-rated oral health among community-dwelling older Japanese: A cross-sectional study. Geriatr. Gerontol. Int. 2015, 15, 755-761.

[21] Chen, Y.; While, A.E.; Hicks, A. Self-rated health and associated factors among older people living alone in Shanghai. Geriatr. Gerontol. Int. 2015, 15, 457-464.

[22] Xin, X.X.; Guan, X.D.; Shi, L.W. Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China. Orphanet. J. Rare Dis. 2016, 11, 74.

[23] Greek-Winald, C.; Gustafsson, B.; Hogvik, L. The Swedish rare disease information database and the Swedish information centre for rare diseases. Orphanet. J. Rare Dis. 2010, 5, O27.

[24] Nicolas, A.; Lucchetti-Miganeh, C.; Yaou, R.B.; Kaplan, J.C.; Chelly, J.; Leturcq, F.; Barloy-Hubler, F.; Le Rumeur, E. Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database. Orphanet. J. Rare Dis. 2012, 7, 45.

[25] Fusco, F.; Paciolla, M.; Conte, M.I.; Pescatore, A.; Esposito, E.; Mirabelli, P.; Lioi, M.B.; Ursini, M.V. Incontinentia pigmenti: report on data from 2000 to 2013. Orphanet. J. Rare Dis. 2014, 9, 93.

[26] Trocello, J. Wilson France: a national database for Wilson’s disease. Orphanet. J. Rare Dis. 2010, 5, 21.

[27] Perehudoff, K.; Toebes, B.; Hogerzeil, H. A human rights-based approach to the reimbursement of expensive medicines. Bull. World Health Organ. 2016, 94, 935-936.

[28] Napoles, A.M.; Ortíz, C.; O’Brien, H.; Sereno, A.B.; Kaplan, C.P. Coping resources and self-rated health among Latina breast cancer survivors. Oncol. Nurs. Forum. 2011, 38, 523-531.

[29] Eng, J.A.; Clough-Gorr, K.; Cabral, H.J.; Silliman, R.A. Predicting 5- and 10-year survival in older women with early-stage breast cancer: self-rated health and walking ability. J. Am. Geriatr. Soc. 2015, 63, 757-762.

[30] Ortiz-Agapito, F.; Colmenares-Bonilla, D. Quality of life of patients with fibrodysplasia ossificans progressiva. J. Child. Orthop. 2015, 9, 489-493.

[31] Moor, I.; Spallek, J.; Richter, M. Explaining socioeconomic inequalities in self-rated health: a systematic review of the relative contribution of material, psychosocial and behavioural factors. J. Epidemiol. Community Health. 2017, 71, 565-575.
[32] Pogany, G. The present situation of Central/Eastern Europe? The role of patient Orphanet. J. Rare Dis. 2010, 5, O30.